WO2006063329A2 - Protection amelioree contre la tuberculose a mycobacteries - Google Patents

Protection amelioree contre la tuberculose a mycobacteries Download PDF

Info

Publication number
WO2006063329A2
WO2006063329A2 PCT/US2005/044871 US2005044871W WO2006063329A2 WO 2006063329 A2 WO2006063329 A2 WO 2006063329A2 US 2005044871 W US2005044871 W US 2005044871W WO 2006063329 A2 WO2006063329 A2 WO 2006063329A2
Authority
WO
WIPO (PCT)
Prior art keywords
lactoferrin
bcg
vaccine
mice
immunized
Prior art date
Application number
PCT/US2005/044871
Other languages
English (en)
Other versions
WO2006063329A3 (fr
Inventor
Jeffrey K. Actor
Marian L. Kruzel
Original Assignee
Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents Of The University Of Texas System filed Critical Board Of Regents Of The University Of Texas System
Publication of WO2006063329A2 publication Critical patent/WO2006063329A2/fr
Publication of WO2006063329A3 publication Critical patent/WO2006063329A3/fr
Priority to US11/810,477 priority Critical patent/US20070259007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Definitions

  • Figure 1 shows that Lactoferrin increases IL-12 production from stimulated macrophages.
  • J774A.1 top or RAW 264.7 cells (bottom) were stimulated with LPS (200 ng/ml) and increasing concentrations of Lactoferrin (1 to 1000 ⁇ g/ml).
  • Supematants were assessed for IL-12 (closed bar) and IL-10 (open bar). Average values (pg/ml) with standard errors are shown. *, p ⁇ 0.05 compared to LPS alone.
  • FIG. 2 shows Stimulation (Proliferation) Index of splenocytes from mice immunized with BCG.
  • Splenocytes from mice immunized one time with BCG in IFA ( ), BCG in IFA with Lactoferrin (100 ⁇ g/mouse) (D), or BCG in CFA (D) were assessed for proliferative response to Heat-Killed BCG. Average Stimulation Index values with standard errors are shown. Responses are compared to non-immunized control mice ( ). *, p ⁇ 0.05; **, p ⁇ 0.05 as measured by two-tailed unpaired Student's t-test for indicated comparisons.
  • FIG. 5 shows that BCG vaccination with adjunct Lactoferrin adjuvant limits mycobacterial dissemination following aerosol challenge with MTB.
  • Mice immunized one time with BCG in IFA ( ), BCG in IFA with Lactoferrin (100 ⁇ g/mouse) ( ), or BCG in CFA ( ) were aerosol challenged with approximately 100 CFU virulent MTB, strain Erdman.
  • Non-immunized controls are indicated (D).
  • 28 days post infection lung tissue left was assessed for bacterial load and spleen tissue (right) was examined for dissemination of organisms to peripheral tissue.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur une nouvelle utilisation de la lactoferrine comme composition adjuvante apte à être utilisée dans des vaccins. En particulier, l'invention concerne l'utilisation de la lactoferrine dans le but d'augmenter l'efficacité du vaccin en provoquant une réponse des lymphocytes T auxiliaires et, par conséquent, une protection contre les attaques d'un pathogène virulent. L'invention se rapporte également à un procédé de fabrication de l'adjuvant et à l'utilisation de ce dernier comme médicament.
PCT/US2005/044871 1999-10-19 2005-12-09 Protection amelioree contre la tuberculose a mycobacteries WO2006063329A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/810,477 US20070259007A1 (en) 1999-10-19 2007-06-06 Lactoferrin: an adjuvant for vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63541404P 2004-12-10 2004-12-10
US60/635,414 2004-12-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/810,477 Continuation-In-Part US20070259007A1 (en) 1999-10-19 2007-06-06 Lactoferrin: an adjuvant for vaccines

Publications (2)

Publication Number Publication Date
WO2006063329A2 true WO2006063329A2 (fr) 2006-06-15
WO2006063329A3 WO2006063329A3 (fr) 2007-01-04

Family

ID=36578658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/044871 WO2006063329A2 (fr) 1999-10-19 2005-12-09 Protection amelioree contre la tuberculose a mycobacteries

Country Status (1)

Country Link
WO (1) WO2006063329A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277817B1 (en) * 1990-03-08 2001-08-21 Ferro Dynamics Inc. Human lactoferrin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277817B1 (en) * 1990-03-08 2001-08-21 Ferro Dynamics Inc. Human lactoferrin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZIMECKI M. ET AL.: 'Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice' IMMUNOLOGY LETTERS vol. 74, 2000, pages 183 - 188, XP003005416 *

Also Published As

Publication number Publication date
WO2006063329A3 (fr) 2007-01-04

Similar Documents

Publication Publication Date Title
US11433106B2 (en) Compositions comprising bacterial strains
US11040075B2 (en) Compositions comprising bacterial strains
US20230173001A1 (en) Compositions comprising bacterial strains
Hwang et al. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis
TWI797058B (zh) 包含細菌菌株之組合物
Pittman The concept of pertussis as a toxin-mediated disease
US20060263380A1 (en) IL-12 as an adjuvant for Bordetella pertussis vaccines
Marzouqi et al. Development of improved vaccines against whooping cough: current status
Renoux et al. Antigenic competition and nonspecific immunity after a rickettsial infection in mice: restoration of antibacterial immunity by phenyl-imidothiazole treatment
Mobarez et al. Induction of protective immunity by recombinant peptidoglycan associated lipoprotein (rPAL) protein of Legionella pneumophila in a BALB/c mouse model
US20070259007A1 (en) Lactoferrin: an adjuvant for vaccines
Xing et al. Nitric oxide induction in murine macrophages and spleen cells by whole-cell Bordetella pertussis vaccine
WO2006063329A2 (fr) Protection amelioree contre la tuberculose a mycobacteries
KR20060118737A (ko) 플라젤린을 포함하는 천식 및 알레르기 질환 면역치료제
Nikokar et al. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model
Sharma et al. Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis
US20070190078A1 (en) Filamentous haemagglutinin in the treatment and/or prophylaxis of immune-mediated disorders
US20060292173A1 (en) Multibacterial vaccines and uses thereof
US20060153869A1 (en) Multibacterial vaccines and uses thereof
JPH05503628A (ja) 新規なワクチン
US7358044B2 (en) Prophylactic and therapeutic benefits of a new class of immune stimulating peptides
Wilk et al. The immunology of Bordetella
JP2006525373A (ja) プロテオソームを用いた感染性疾患に対する予防接種
Goel Interleukin-6 Contributes To Immunity Against Bordetella Pertussis.
STOUT et al. 1. THE DISEASE

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 11810477

Country of ref document: US

NENP Non-entry into the national phase in:

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 11810477

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 05853720

Country of ref document: EP

Kind code of ref document: A2